The abstract is read at the publisher; the summary is JClub's.
Prenatal miransertib treatment rescued embryonic lethality in mosaic Akt1 E17K (Akt1 c.49G>A) mice, increasing neonatal survival at 60–90 mg/kg/day (15/63 vs 6/152).
- Why it matters: Proteus syndrome involves constitutive AKT1 activation, and ubiquitous Akt1 E17K expression causes embryonic lethality, leaving a need to test whether small molecules can rescue development.
- What they did: The study tested placental crossing of miransertib and dosed pregnant dams at defined gestational time points, then measured neonatal survival from timed matings in ACTB-Cre; Akt1 WT/flx embryos.
- The result: Treatment at 60 or 90 mg/kg/day significantly increased neonatal survival (p=0.0003), and some mutant βA-Akt1 WT/flx offspring remained apparently healthy until nearly 18 months without postnatal dosing.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.